05.09.2017 • NewsElaine BurridgeEastmanCopolyester

Eastman Chemical Hikes CHDM Capacity

(c) Eastman
(c) Eastman

Eastman Chemical has announced it will undertake a series of projects at its site in Kingsport, Tennessee, USA, to raise capacity for cyclohexanedimethanol (CHDM), a precursor for producing polyesters.

A program of debottlenecks and expansions will take place during the next 18 months, increasing output capability by 15,000 t/y overall. All projects are anticipated to be completed by early 2019. Eastman said the investments will enable it to meet increasing demand for copolyesters as well as other polyester products.

Burt Capel, vice president and general manager of Eastman’s Specialty Plastics business, commented: “Since its launch, we’ve seen tremendous growth in Tritan and continued strength across our copolyester product portfolio. This investment, along with the additional PETG capacity we recently announced that is coming online in 2018, further demonstrates our commitment to our entire copolyester business.”

Last month, the company said it planned to expand PETG capacity by approximately 20% at its copolyester site in Kuantan, Malaysia. The expansion is scheduled for completion in the first quarter of 2018.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.